Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORINYL 1+80 21-DAY vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy (FDA-approved)
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol undergoes first-pass metabolism in the intestinal wall and liver via CYP3A4, with conjugation and enterohepatic recirculation. Norethindrone is metabolized in the liver primarily via reduction and conjugation, with CYP3A4 involvement. Both are excreted in urine and feces.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (40-60% as metabolites), fecal (20-30%)
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: 61% bound to albumin and SHBG; Mestranol/ethinyl estradiol: 98% bound to albumin
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: 3.6 L/kg; Mestranol/ethinyl estradiol: 1.5-4.0 L/kg
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: norethindrone ~64%; mestranol ~40-60% (prodrug, converted to ethinyl estradiol)
Oral: ~70% due to first-pass metabolism.
No specific dose adjustment required for renal impairment. Use with caution in patients with renal dysfunction.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in severe hepatic disease (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use only if benefits outweigh risks and monitor liver function closely.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For adolescents post-menarche, same adult dosing: one tablet orally once daily for 21 days, then 7-day pill-free interval.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. No specific dose adjustments in elderly women of reproductive age; standard adult dosing applies.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events. Risk increases with age (especially >35 years) and heavy smoking (≥15 cigarettes/day). Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic events (venous thromboembolism, stroke, MI),Cigarette smoking,Hypertension,Gallbladder disease,Hepatic neoplasia,Carbohydrate/lipid effects,Headache/migraine,Bleeding irregularities,Use in pregnancy,Diabetes,Depression,Hereditary angioedema,Chloasma,Hepatic impairment,Renal impairment,Breast cancer risk
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Carcinoma of endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Active liver disease with abnormal liver function,Hypersensitivity to any component,Diabetes with vascular involvement,Uncontrolled hypertension,Major surgery with prolonged immobilization,Migraine with focal aura or over age 35 with any migraine
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No significant food interactions. Grapefruit juice may slightly increase estrogen levels but effect is minimal. Maintain consistent intake to avoid gastrointestinal upset.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
First trimester: No conclusive evidence of major malformations from combined hormonal contraceptives; however, data are limited. Second/third trimester: Use is contraindicated due to possible adverse effects on fetal development, including potential masculinization of female genitalia (androgenic progestin) and other hormonal effects, though the risk is low with norethindrone. Postnatal: No specific long-term effects documented.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Small amounts of norethindrone and ethinyl estradiol excreted in breast milk; M/P ratio not established. Use is not recommended during breastfeeding as estrogen may reduce milk production and quality; progestin-only contraception preferred.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dose adjustments are applicable; use is contraindicated during pregnancy. If unintended pregnancy occurs, immediate discontinuation is advised.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
NORINYL 1+80 21-DAY is a high-estrogen-dose combination oral contraceptive (1 mg norethindrone, 80 mcg mestranol). Use with caution in patients with cardiovascular risk factors; contraindicated in women over 35 who smoke. Mestranol is a prodrug that requires hepatic conversion to ethinyl estradiol; lower potency compared to ethinyl estradiol on a mcg basis. Monitor for thromboembolic events, especially in the first year of use. Consider alternative formulations if breakthrough bleeding occurs.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time each day for 21 days, then no tablets for 7 days.,If you miss a pill, follow the package instructions; use backup contraception as directed.,This medication does not protect against HIV or other sexually transmitted infections.,Seek immediate medical attention for sudden chest pain, shortness of breath, leg pain or swelling, severe headache, or vision changes.,Inform your healthcare provider if you smoke or have a history of blood clots, migraines, or hypertension.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORINYL 1+80 21-DAY vs AFIRMELLE, answered by our medical review team.
NORINYL 1+80 21-DAY is a Oral Contraceptive that works by Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORINYL 1+80 21-DAY and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORINYL 1+80 21-DAY is: One tablet orally once daily for 21 days, followed by 7 days of no active treatment.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORINYL 1+80 21-DAY and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORINYL 1+80 21-DAY is classified as Category C. First trimester: No conclusive evidence of major malformations from combined hormonal contraceptives; however, data are limited. Second/third trimester: Use is contraindicated due . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.